UPDATE: JPMorgan Downgrades ChemoCentryx (CCXI) to Underweight
- Wall Street stocks fall as weak GDP growth spreads rate-cut gloom
- Q1 US GDP shows surprise slowing and uncomfortable inflation
- Meta shares dip on softer Q2 revenue guidance, elevated AI spending plans
- Oil settles higher as weak U.S. economic growth offset by supply concerns
- Dollar sags after US GDP and inflation surprise, except against yen
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hasbro (HAS) brand strength sees earnings top expectations
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
ChemoCentryx (CCXI) Crashes 55% on Mixed AdComm Results, Gets Downgraded at Five Firms
May 7, 2021 9:36 AM EDTShares of ChemoCentryx (NASDAQ: CCXI) crashed 55% in pre-open Friday after the Food and Drug Administration (FDA) raised concerns over the approval application of the product avacopan.
We are grateful to the Committee for their careful deliberations and look forward to working with the FDA as its review of our application continues, said Thomas J. Schall, Ph.D., President and Chief Executive Officer of ChemoCentryx. Discussion from patients and clinicians during the public forum portion of the meeting underscored the need for new treatment options.
The FDA is primarily concerned that the therapy could not... More
Raymond James Downgrades ChemoCentryx (CCXI) to Outperform
May 7, 2021 7:38 AM EDTRaymond James analyst Steven Seedhouse downgraded ChemoCentryx (NASDAQ: CCXI) from Strong Buy to Outperform with a price target of $51.00 (from $120.00).
The analyst commented, "To be clear, our downgrade to Outperform from Strong Buy is based on reduced conviction in avacopan being approved by July 7 PDUFA given Thursdays AdCom discussion and vote. However, if approved we still think avacopan is a... More
ChemoCentryx (CCXI) sinks 45% as trading resumes following mixed FDA AdCom
May 7, 2021 7:15 AM EDTChemoCentryx (NASDAQ: CCXI) sinks 45% as trading resumes following mixed FDA AdCom.
... MoreChemoCentryx (CCXI) Reports Mixed FDA AdCom Vote For Avacopan
May 7, 2021 6:48 AM EDTChemoCentryx, Inc., (Nasdaq: CCXI), today announced the outcome of the FDA Arthritis Advisory Committee on avacopan for the treatment of Antineutrophil Cytoplasmic Autoantibody (ANCA)-associated vasculitis (or AAV). In the final part of the public meeting, the Committee voted on three questions presented by the FDA:
The Committee vote split 9-9 on the first question, whether the efficacy data support approval of avacopan for the treatment of adult patients with AAV (granulomatosis with... More
UPDATE: Stifel Downgrades ChemoCentryx (CCXI) to Hold
May 7, 2021 4:01 AM EDT(Updated - May 7, 2021 5:14 AM EDT)
Stifel analyst Dae Gon Ha downgraded ChemoCentryx (NASDAQ: CCXI) from Buy to Hold with a price target of $26.00 (from $93.00).
THe analyst comments "We are downgrading CCXI to Hold (from Buy) with a reduced TP $26 (from $93 previously) following a... More
Piper Sandler Downgrades ChemoCentryx (CCXI) to Neutral
May 6, 2021 7:04 PM EDTPiper Sandler analyst Edward Tenthoff downgraded ChemoCentryx (NASDAQ: CCXI) from Overweight to Neutral with a price target of $25.00.
For an analyst ratings summary and ratings history on ChemoCentryx click here. For more ratings news on ChemoCentryx click here.
Shares of ChemoCentryx closed at $27.49 yesterday.
... MoreChemoCentryx (CCXI) Halted, News Pending
May 6, 2021 6:55 AM EDTChemoCentryx (NASDAQ: CCXI) Halted, News Pending
... More